Based on Genentech Inc.'s Phase I data presented last week at the American Society of Clinical Oncology meeting, the Roche unit could see swift uptake of its anti-PD-L1 antibody in the underserved indication of metastatic bladder cancer.

It has been more than 20 years since any new drugs were approved for metastatic bladder cancer, for which first-line standard of care is platinum-based chemotherapy.